Literature DB >> 6090051

Elimination kinetics of disulfiram in alcoholics after single and repeated doses.

M D Faiman, J C Jensen, R B Lacoursiere.   

Abstract

Elimination kinetics of disulfiram were determined in 15 male alcoholics after 250 mg disulfiram taken by mouth as a single dose and again after 12 days of dosing. Apparent t 1/2s were calculated for disulfiram, diethyldithiocarbamate (DDTC), diethyldithiocarbamate-methyl ester (DDTC-Me), diethylamine (DEA), and carbon disulfide (CS2) and were found to be 7.3, 15.5, 22.1, 13.9, and 8.9 hr. Elimination t 1/2 for CS2 in breath was 13.3 hr. Average time to reach maximal plasma concentration after either single or repeated doses was 8 to 10 hr for disulfiram, DDTC, DDTC-Me, DEA, and CS2 in breath, while plasma CS2 concentration peaked 5 to 6 hr after disulfiram. In these studies, 22.4% and 31.3% of the disulfiram after single and repeated dosing was eliminated in the breath during one dosing interval. In urine, 1.7% and 8.3% of the disulfiram dose was eliminated as DDTC-glucuronide after single and repeated dosing, while DEA accounted for 1.6% and 5.7% of the dose. There was marked intersubject variability in plasma levels of disulfiram and its metabolites. This variability may be the result of the lipid solubility of disulfiram, differences in plasma protein binding, or the effect of enterohepatic cycling.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090051     DOI: 10.1038/clpt.1984.213

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry.

Authors:  Jill Hochreiter; Elinore F McCance-Katz; Jill Lapham; Qing Ma; Gene D Morse
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-04-01       Impact factor: 3.205

2.  Disulfiram and Copper Ions Kill Mycobacterium tuberculosis in a Synergistic Manner.

Authors:  Alex G Dalecki; Mehri Haeili; Santosh Shah; Alexander Speer; Michael Niederweis; Olaf Kutsch; Frank Wolschendorf
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

3.  Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.

Authors:  Elinore F McCance-Katz; Valerie A Gruber; George Beatty; Paula Lum; Qing Ma; Robin DiFrancesco; Jill Hochreiter; Paul K Wallace; Morris D Faiman; Gene D Morse
Journal:  Am J Addict       Date:  2013-10-11

4.  Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Authors:  Sulggi A Lee; Julian H Elliott; James McMahon; Wendy Hartogenesis; Namandje N Bumpus; Jeffrey D Lifson; Robert J Gorelick; Peter Bacchetti; Steven G Deeks; Sharon R Lewin; Radojka M Savic
Journal:  Clin Pharmacol Ther       Date:  2018-10-09       Impact factor: 6.875

5.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

6.  Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.

Authors:  Lachlan R Gray; Hung On; Emma Roberts; Hao K Lu; Michael A Moso; Jacqueline A Raison; Catherine Papaioannou; Wan-Jung Cheng; Anne M Ellett; Jonathan C Jacobson; Damian F J Purcell; Steve L Wesselingh; Paul R Gorry; Sharon R Lewin; Melissa J Churchill
Journal:  J Neurovirol       Date:  2016-01-04       Impact factor: 2.643

7.  Disulfiram causes selective hypoxic cancer cell toxicity and radio-chemo-sensitization via redox cycling of copper.

Authors:  Kelly C Falls-Hubert; Aimee L Butler; Kai Gui; Michael Anderson; Mengshi Li; Jeffrey M Stolwijk; Samuel N Rodman; Shane R Solst; Ann Tomanek-Chalkley; Charles C Searby; Val C Sheffield; Vanessa Sandfort; Hartmut Schmidt; Michael L McCormick; Brian R Wels; Bryan G Allen; Garry R Buettner; Michael K Schultz; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2020-02-04       Impact factor: 7.376

8.  Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.

Authors:  Rajesh Ramakrishnan; Hongbing Liu; Andrew P Rice
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

9.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

10.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.